Edgewise Therapeutics Inc. (EWTX) exhibits 41.0% gross margins and -31.9% return on invested capital within Health Care (Biotechnology: Pharmaceutical Preparations), balanced against a 24.0x enterprise multiple and 7.2% implied options volatility.
Sustained 41.0% gross profitability converts into -16.2% operating margin and -31.9% ROIC, outpacing sector cost of capital.
ROIC: -31.9% // GM: 41.0%YoY revenue trajectory of -1.1% paired with -3.41% free cash flow yield supports self-funded R&D and capital return.
REV YOY: -1.1% // FCF YLD: -3.41%Altman Z-Score of 26.00 and Piotroski F-Score of 3/9 indicate low near-term refinancing stress.
ALTMAN Z: 26.00 // F-SCORE: 3/9Trading at 24.0x trailing P/E (25.0x Fwd P/E) leaves valuation vulnerable if real 10Y TIPS yields spike.
P/E: 24.0x // EV/EBITDA: —Options market prices a ±7.2% implied move with a 1.03 put/call ratio around $38.00 max pain.
IMPL MOVE: ±7.2% // P/C: 1.03Elevated industry capital intensity and customer concentration in Biotechnology: Pharmaceutical Preparations require continuous execution to defend 0.0% net margins.
NET MARGIN: 0.0% // D/E: 0.02x| FILER | SIDE | $ VALUE |
|---|---|---|
| INSPECT FULL OWNERSHIP LEDGER IN OWN <GO> | ||
| STRIKE / EXP | TYPE | PREMIUM |
|---|---|---|
| INSPECT GEX & CHAIN IN OPT <GO> | ||
Unblur the exact $50,000 delta-adjusted ETF/options hedge ratio for EWTX & activate live FRED threshold breach alerts.